Home » Samaritan Pharma Signs Licensing Agreement With Georgetown University for SP-6300 Drug
Samaritan Pharma Signs Licensing Agreement With Georgetown University for SP-6300 Drug
Samaritan Pharmaceuticals, Inc. on Wednesday said it entered an exclusive licensing agreement with Georgetown University for a new innovative drug called SP-6300 to treat Cushing’s syndrome, sometimes called as hypercortisolism.
RTTNews
Upcoming Events
-
07May
-
14May
-
30May